ClinicalTrials.Veeva

Menu

Post-hoc Analysis of Regional Pulmonary Perfusion and Hemodynamic Parameters Measured by Electrical Impedance Tomography

D

Dräger

Status

Suspended

Conditions

Ventilation Perfusion Mismatch
Mechanical Ventilation

Treatments

Device: PulmoVista 500

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT04249414
PV500PERF

Details and patient eligibility

About

Define the capability and reliability of the PulmoVista® 500 (PV500) to detect changes in global and regional ventilation and perfusion.

Full description

The results of this study will help defining the capability and reliability of PulmoVista® 500 (PV500) to detect changes in both global and regional ventilation and perfusion. As this is a non-invasive, observational trial, neither a positive nor a negative impact on the actual study participants is expected. The results will, however, improve the knowledge about the electrical impedance tomography (EIT) technology and thus aid the use of this technology for the benefit of future patients.

Enrollment

22 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age 18 - 80 years
  • Mandatorily ventilated intensive-care patients with impairment in oxygenation (P/F ratio < 300 at PEEP ≥ 5) ventilated at a positive end-expiratory pressure (PEEP) not exceeding 10 mbar and an fraction of inspired oxygen (FiO2) chosen, such that pulse oximetry is sensitive towards arterial oxygen pressure (PaO2) changes.
  • Expected ventilation time >48h
  • Existing central venous and arterial access
  • Chest circumference 70 - 150 cm
  • Mandatory mechanical ventilation (patients without spontaneous efforts)
  • Serum levels of sodium and chloride within normal range
  • Cardiac output monitoring in place (PICCO)

Exclusion criteria

  • Contraindication to central venous injection of 5 % sodium chloride (NaCl) (e.g. elevated Na+ and/or Cl- concentration: Na+ should not exceed 150 mmol/l, Chloride should not exceed 115 mmol/l, known hypernatremia, known high serum osmolality)

  • Contraindications of PulmoVista 500:

    • Patients with pacemakers, defibrillators or other electrically active implants
    • Patients with damaged skin or impaired skin contact of the electrodes due to wound dressings
    • Patients where the attachment of the patient belt could pose a risk to the patient, e.g. patients with spinal lesions or fractures
    • Patients with uncontrolled body movements
    • Extremely obese patients (BMI>50)
    • Patients during pregnancy
    • Patients with massive lung edema
    • Use during electricity-based therapies, such as electrosurgery or electrocautery
    • Use in the presence of strong magnetic fields
    • Use in conjunction with other bioimpedance measurement devices
  • Infection or colonization with multi-resistant pathogens that require isolation of the patient (e.g. MRSA)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems